Loading organizations...
TriAgenics is a medical device company developing a preventive dental solution for wisdom teeth. Its core product, Zero3® TBA (3rd Molar Tooth Bud Ablation), is a minimally invasive treatment designed to stop wisdom teeth from ever forming. The technology utilizes a targeted, gentle warming approach to ablate the developing tooth buds, aiming to circumvent future extractions.
Co-founded by Leigh Colby, Chief Clinical Officer, and Dave Watson, Chief of Operations, TriAgenics emerged from Dr. Colby’s clinical insight as a dental practitioner for proactive wisdom tooth management. Mr. Watson, with engineering and product development expertise, guided the solution’s technical realization.
TriAgenics targets dentists and parents for children aged 6-12, offering a proactive approach to oral health. By providing a preventative alternative to traditional extraction, the company aims for patients to avoid common wisdom tooth pathologies and risks. Its vision is to deliver a safer, more effective, and simpler method for wisdom tooth management, transforming care.
Triagenics has raised $3.0M across 1 funding round.
Triagenics has raised $3.0M in total across 1 funding round.
TriAgenics is a pre-revenue medical device company developing the Zero3 TBA system, a minimally invasive, one-minute dental treatment that uses targeted thermal energy to ablate third molar (wisdom tooth) buds in children aged 6-12, preventing wisdom teeth from ever forming and eliminating the need for future surgical extractions.[1][2][3][5] It serves general dentists and pediatric patients, addressing the widespread issues of wisdom tooth-related pain, swelling, complications, recovery time, and associated diseases by offering a non-surgical alternative with no observed adverse outcomes beyond one post-op infection in animal trials.[1][2][5] Headquartered in Redmond, Oregon, with three employees and consultants, the company has raised over $12.5 million in Series A funding and $3 million in Series B-1 as of mid-2025, while pursuing FDA De Novo clearance to launch in the U.S. market.[1][2][3][4]
TriAgenics emerged from the vision of CEO Leigh Colby, D.D.S., a dentist who identified third molar management as a major pain point for general practitioners, aiming to create a simple, non-surgical solution.[1] The company, founded prior to its 2023 SEC filings, developed the Zero3 TBA technology based on extensive animal trials demonstrating safe, effective tooth bud ablation with zero detectable tooth formation post-treatment.[2][5] Key early traction includes building a robust IP portfolio—now at 37 issued U.S. and international patents protecting the technology across the U.S., Canada, Mexico, Australia, and Europe—and securing progressive funding rounds, culminating in a $5 million Series A-3 and $3 million Series B-1 led by Asclepius Ventures in July 2025 to support FDA review and premarket research.[1][2][3]
TriAgenics rides the medtech trend toward minimally invasive, preventive dentistry, capitalizing on rising demand for patient-centric solutions that reduce surgical risks amid growing awareness of wisdom teeth complications affecting millions annually.[1][2] Timing aligns with FDA's De Novo pathway for novel devices and post-pandemic shifts favoring quick, low-recovery procedures, bolstered by Align Technology's playbook of empowering generalists with scalable tools.[2] Market forces like dentist shortages and high extraction costs (often requiring time off work/school) favor its in-house model, potentially disrupting a multi-billion-dollar oral surgery sector while influencing ecosystems through IP expansion and global partnerships.[1][3]
Post-FDA clearance expected soon, TriAgenics will prioritize U.S. dentist rollout for cash-flow positivity, then international expansion leveraging its 37 patents.[2][3] Trends like AI-driven dental imaging and pediatric preventive care will accelerate adoption, evolving its influence from niche innovator to potential industry standard by 2030.[1] Success hinges on regulatory wins, but its Align-inspired model positions it to transform wisdom tooth management, delivering lifelong health gains without the scalpel.
Triagenics has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Series B in July 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2025 | $3M Series B | — | Florida Funders, Galen Partners, Sands Capital | Announced |
Triagenics has raised $3.0M in total across 1 funding round.
Triagenics's investors include Florida Funders, Galen Partners, Sands Capital.
